Pharsight

1. Cardene In 0.83% Sodium Chloride In Plastic Container patents expiration

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US7612102	October, 2014	Terminated-Denied	EKR Therapeutics, LLC	Sandoz Inc.
US7659291	October, 2014	Terminated-Denied	EKR Therapeutics, LLC	Sandoz Inc.
US8455524	October, 2014	Terminated-Denied	EKR Therapeutics, LLC	Sandoz Inc.

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7659291	CHIESI	Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions	Apr, 2027 (2 years from now)
US11547758	CHIESI	Pre-mixed, ready-to-use pharmaceutical compositions	Apr, 2027 (2 years from now)
US8455524	CHIESI	Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions	Apr, 2027 (2 years from now)
US10758616	CHIESI	Pre-mixed, ready-to-use pharmaceutical compositions	Apr, 2027 (2 years from now)
US9364564	CHIESI	Pre-mixed, ready-to-use pharmaceutical compositions	Dec, 2027 (3 years from now)
US7612102	CHIESI	Pre-mixed, ready-to-use pharmaceutical compositions	Dec, 2027 (3 years from now)

Market Authorisation Date: 30 January, 1992

Treatment: Method for treating acute elevations of blood pressure in human subject in need thereof

Dosage: INJECTABLE;INTRAVENOUS

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
2.5 mg/mL, 10 mL Ampoules	27 Dec, 2006	1
0.1 mg/mL, 200 mL 0.2mg/mL, 200 mL	09 Jan, 2013	1		26 Dec, 2027

Strength	Dosage	Availability
40MG/200ML (0.2MG/ML)	INJECTABLE;INTRAVENOUS	Prescription

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US7612102	October, 2014	Terminated-Denied	EKR Therapeutics, LLC	Sandoz Inc.
US7659291	October, 2014	Terminated-Denied	EKR Therapeutics, LLC	Sandoz Inc.
US8455524	October, 2014	Terminated-Denied	EKR Therapeutics, LLC	Sandoz Inc.

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7659291	CHIESI	Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions	Apr, 2027 (2 years from now)
US11547758	CHIESI	Pre-mixed, ready-to-use pharmaceutical compositions	Apr, 2027 (2 years from now)
US8455524	CHIESI	Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions	Apr, 2027 (2 years from now)
US10758616	CHIESI	Pre-mixed, ready-to-use pharmaceutical compositions	Apr, 2027 (2 years from now)
US7612102	CHIESI	Pre-mixed, ready-to-use pharmaceutical compositions	Dec, 2027 (3 years from now)
US9364564	CHIESI	Pre-mixed, ready-to-use pharmaceutical compositions	Dec, 2027 (3 years from now)

Market Authorisation Date: 30 January, 1992

Treatment: Method for treating acute elevations of blood pressure in human subject in need thereof

Dosage: INJECTABLE;INTRAVENOUS

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
2.5 mg/mL, 10 mL Ampoules	27 Dec, 2006	1
0.1 mg/mL, 200 mL 0.2mg/mL, 200 mL	09 Jan, 2013	1		26 Dec, 2027

Strength	Dosage	Availability
20MG/200ML (0.1MG/ML)	INJECTABLE;INTRAVENOUS	Prescription

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US7612102	October, 2014	Terminated-Denied	EKR Therapeutics, LLC	Sandoz Inc.
US7659291	October, 2014	Terminated-Denied	EKR Therapeutics, LLC	Sandoz Inc.
US8455524	October, 2014	Terminated-Denied	EKR Therapeutics, LLC	Sandoz Inc.

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11547758	CHIESI	Pre-mixed, ready-to-use pharmaceutical compositions	Apr, 2027 (2 years from now)
US8455524	CHIESI	Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions	Apr, 2027 (2 years from now)
US10758616	CHIESI	Pre-mixed, ready-to-use pharmaceutical compositions	Apr, 2027 (2 years from now)
US7659291	CHIESI	Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions	Apr, 2027 (2 years from now)
US9364564	CHIESI	Pre-mixed, ready-to-use pharmaceutical compositions	Dec, 2027 (3 years from now)
US7612102	CHIESI	Pre-mixed, ready-to-use pharmaceutical compositions	Dec, 2027 (3 years from now)

Market Authorisation Date: 30 January, 1992

Treatment: Method for treating acute elevations of blood pressure in human subject in need thereof

Dosage: INJECTABLE;INTRAVENOUS

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
2.5 mg/mL, 10 mL Ampoules	27 Dec, 2006	1
0.1 mg/mL, 200 mL 0.2mg/mL, 200 mL	09 Jan, 2013	1		26 Dec, 2027

Strength	Dosage	Availability
20MG/200ML (0.1MG/ML)	INJECTABLE;INTRAVENOUS	Prescription

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US7612102	October, 2014	Terminated-Denied	EKR Therapeutics, LLC	Sandoz Inc.
US7659291	October, 2014	Terminated-Denied	EKR Therapeutics, LLC	Sandoz Inc.
US8455524	October, 2014	Terminated-Denied	EKR Therapeutics, LLC	Sandoz Inc.

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8455524	CHIESI	Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions	Apr, 2027 (2 years from now)
US7659291	CHIESI	Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions	Apr, 2027 (2 years from now)
US9364564	CHIESI	Pre-mixed, ready-to-use pharmaceutical compositions	Dec, 2027 (3 years from now)
US7612102	CHIESI	Pre-mixed, ready-to-use pharmaceutical compositions	Dec, 2027 (3 years from now)

Market Authorisation Date: 30 January, 1992

Treatment: Method for treating acute elevations of blood pressure in human subject in need thereof

Dosage: INJECTABLE;INTRAVENOUS